KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Castle Biosciences (CSTL) over the last 8 years, with Q2 2025 value amounting to $2.2 million.

  • Castle Biosciences' Gains from Investment Securities rose 25317.07% to $2.2 million in Q2 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 7296.03%. This contributed to the annual value of $8.8 million for FY2024, which is 7066.61% up from last year.
  • Latest data reveals that Castle Biosciences reported Gains from Investment Securities of $2.2 million as of Q2 2025, which was up 25317.07% from $2.5 million recorded in Q1 2025.
  • Over the past 5 years, Castle Biosciences' Gains from Investment Securities peaked at $6.4 million during Q4 2024, and registered a low of -$20.4 million during Q2 2022.
  • In the last 5 years, Castle Biosciences' Gains from Investment Securities had a median value of $954500.0 in 2024 and averaged $137357.1.
  • Over the last 5 years, Castle Biosciences' Gains from Investment Securities had its largest YoY gain of 786363.64% in 2022, and its largest YoY loss of 11217.04% in 2022.
  • Over the past 5 years, Castle Biosciences' Gains from Investment Securities (Quarter) stood at $2.5 million in 2021, then plummeted by 112.17% to -$300000.0 in 2022, then skyrocketed by 1438.33% to $4.0 million in 2023, then skyrocketed by 58.88% to $6.4 million in 2024, then tumbled by 65.95% to $2.2 million in 2025.
  • Its Gains from Investment Securities was $2.2 million in Q2 2025, compared to $2.5 million in Q1 2025 and $6.4 million in Q4 2024.